Wow.
Interesting. Mayor bail, major shorting. Huge chunk of the company goes out the door at 6.50 and here we are at 5.70 with a circuit breaker in place.
Looks like Chimera again, playing prtk bingo. Just waiting for downside, oral side effects? Literature continues to look good, here's the latest.....
Int J Antimicrob Agents. 2017 Jul 10. pii: S0924-8579(17)30271-6. doi: 10.1016/j.ijantimicag.2017.06.022. [Epub ahead of print]
In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.
Seifert H1, Stefanik D2, Sutcliffe JA3, Higgins PG4.
Author information
1Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Germany. Electronic address: harald.seifert@uni-koeln.de.2Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.3Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.4Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Germany.
Abstract
The activity of eravacycline was compared with anti-Acinetobacter reference antimicrobials against carbapenem non-susceptible Acinetobacter baumannii isolates associated with an acquired OXA or up-regulation of the intrinsic OXA-51-like enzyme. Antimicrobial susceptibility testing was performed by broth microdilution of 286 non-duplicate, carbapenem non-susceptible A. baumannii isolates to eravacycline, amikacin colistin, doxycycline, imipenem, levofloxacin, meropenem, minocycline, sulbactam, tigecycline, and tobramycin. Eravacycline showed greater activity than the comparators of the tetracycline class, levofloxacin, amikacin, tobramycin, and colistin. The eravacycline MIC50/90 values were 0.5/1 mg/L. Comparatively, tigecycline, minocycline and doxycycline MIC50/90 values were 1/2, 4/8, 32/=64 mg/L, respectively. In conclusion, eravacycline was the most potent antibiotic against A. baumannii, including isolates that were resistant to sulbactam, imipenem/meropenem, levofloxacin, and amikacin/tobramycin, compared to other compounds. It has the potential to become a useful addition to the limited armamentarium of drugs that can be used to treat this problem pathogen. |
